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Abstract
Importance—Controversy remains about whether depression can be successfully managed after
acute coronary syndrome (ACS) and the costs and benefits of doing so.
Objective—To determine the effects of providing post-ACS depression care on depressive
symptoms and health care costs.
Design, Setting, and Participants—We performed a multicenter randomized controlled trial
with 150 patients with elevated depressive symptoms (Beck Depression Inventory [BDI] score
≥10) 2 to 6 months after an ACS. Patients were recruited from 2 private and 5 academic
ambulatory centers across the United States between March 18, 2010, and January 9, 2012.
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Intervention(s)—Patients were randomized to 6 months of centralized depression care (patient
preference for problem-solving treatment given via telephone or the Internet, pharmacotherapy,
both, or neither), stepped every 6 to 8 weeks, (active treatment group; n=73) or to locally
determined depression care after physician notification about the patient’s depressive symptoms
(usual care group; n=77).
Main Outcome Measure(s)—Change in depressive symptoms during 6 months and total health
care costs.
Results—Depressive symptoms decreased significantly more in the active treatment group than
in the usual care group (differential change between groups, −3.5 BDI points; 95% CI, −6.1 to
−0.7; P = .01). Although mental health care estimated costs were higher for active treatment than
for usual care, overall health care estimated costs were not significantly different (difference
adjusting for confounding, −$325; 95% CI, −$2639 to $1989; P=.78).
Conclusions—For patients with post-ACS depression, active treatment had a substantial
beneficial effect on depressive symptoms. This kind of depression care is feasible, effective, and
may be cost-neutral within 6 months; therefore, it should be tested in a large phase 3 pragmatic
trial.
Trial Registration—clinicaltrials.gov Identifier: NCT01032018
Depression will soon be the leading cause of years lived with disability worldwide1 and
contributes even more to disability when comorbid with a chronic medical disorder.2,3 Every
year, approximately 1.2 million Americans survive an acute coronary syndrome (ACS)
event,4 and many have clinically significant and persistent depression.5,6 Patients with post-
ACS depression have significantly more ambulatory medical appointments, emergency
department visits, and higher health care costs than similar patients without depression.7,8
Post-ACS depression is also associated with a 150% increased risk of ACS recurrence9 and
a 100% increase in the relative risk of all-cause mortality,2,10,11 and persistent depression
after an ACS event is associated with an even higher morbidity and mortality risk.3,12
Reducing persistent post-ACS depression is therefore an important public health objective.
Despite its importance, routine management of post-ACS depression remains poor12,13
because of inefficiencies in depression screening,12 lack of effective administration of
depression treatment,12 weak depression treatment effects, and limited treatment options if
initial efforts fail.14 Published trials have yet to demonstrate clinically significant depressive
symptom reduction, have not tested strategies that would be feasible in clinical practice, are
not cost-effective, and do not incorporate the preferences of ACS patients for either
psychotherapy or psychotropic medications into their treatment algorithms.15
The Comparison of Depression Interventions after Acute Coronary Syndrome (CODIACS)
Vanguard trial was designed to determine the feasibility, efficacy, and costs of a centralized,
stepped, patient preference–based depression care system for ACS patients. This system
provides depression treatment several months after an ACS, when most transient depressive
reactions to ACS have spontaneously remitted but prognostic risk of ongoing depression
symptoms is still high. It follows a treatment strategy that incorporates patient preference,
adjusts treatment in a stepped manner as symptoms require, and centralizes the provision of
care by highly trained depression specialists. We hypothesized that this approach would be
cost-effective and produce larger reductions in depression than ad lib or usual care provided
in the patient’s community.
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SETTING AND STUDY PARTICIPANTS
Briefly, this study was a feasibility, parallel-group, comparative effectiveness randomized
controlled trial (RCT), with masked outcome assessments, in patients with persistent
depressive symptoms following an ACS. The study tested whether centralized, patient
preference–based depression care is cost-effective and results in larger depressive symptom
reductions compared with locally administered, ad lib depression care. Participants were
recruited from sites connected with 5 field centers (Columbia University, New York, New
York; Washington University, St Louis, Missouri; University of Pennsylvania, Philadelphia;
Emory University, Atlanta, Georgia; and Yale University, New Haven, Connecticut) from
March 18, 2010, to January 9, 2012. To be eligible, participants had to demonstrate elevated
depressive symptoms on the Beck Depression Inventory I (BDI)16 (BDI score ≥10 on 2
screening occasions or >15 on 1 occasion) 2 to 6 months after hospitalization for an ACS
(ie, unstable angina or myocardial infarction) defined by standard criteria,17,18 be at least 35
years old, and be fluent in English or Spanish. Exclusion criteria were set for safety,
retention, or intervention futility reasons (see Whang et al19 for details). The CODIACS
Vanguard evaluated different recruitment strategies at different sites; details about each
site’s recruitment strategy and our conclusions about the most efficient recruiting strategy
can be found elsewhere.20 Briefly, automated searches of electronic medical records were
conducted at most sites to identify patients who met the trial’s ACS and other medical
criteria. Potential participants were then approached by a research coordinator or physician
for further screening. Institutional review board–approved, written informed consent for
participation was obtained before the screening interview and before randomization.
RANDOMIZATION
Participants were randomized in a 1:1 ratio according to a computer-generated, permuted-
block randomization scheme, stratified by site and current antidepressant use, that local
research assistants accessed by telephone. Patients were randomized to receive 6 months of
centralized, stepped, patient preference–based treatment (active treatment group) or locally
administered, ad lib depression care (usual care group). If randomized to the active treatment
group, an unmasked research assistant met with the participant to discuss the relative
benefits and risks of psychotherapy and medication use, and the participant’s initial choice
was then provided.
OUTCOME MEASURES AND MASKING
Research assistants who were masked to randomization administered the BDI and
ascertained adverse events, mental health and hospitalization information, and medication
use at baseline and 6 months during in-person interviews and at 2 and 4 months by
telephone. Patients and clinicians were not masked to group status.
TREATMENT GROUPS
The active treatment was provided by a team of professionals, including a centralized
problem-solving treatment (PST) therapist, centralized psychiatry and clinical psychology
supervisors, and a local study physician or advanced practice registered nurse responsible
for prescribing and managing antidepressant medications. The team met weekly to discuss
clinical issues, treatment quality reviews, and stepped care decisions for the active treatment
participants. The Patient Health Questionnaire 9 (PHQ-9)21 was administered to participants
at each study treatment session to monitor depressive symptoms and determine symptom
improvement relative to baseline. If the minimum prespecified improvement criterion (see
Whang et al19 for details) had not been achieved during the step period (6–8 weeks), the
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team offered suggestions for subsequent treatment to the clinician, and additional or
alternative treatments were subsequently initiated with patient agreement. Additional
treatment steps were made every 6 to 8 weeks with the aim of achieving the criterion of
depression treatment success (PHQ-9 score ≤3 for 2 consecutive weeks) by the end of the
intervention. Depression symptom monitoring and maintenance therapy continued on a
prespecified schedule (weekly, then monthly) for the 6-month duration of the trial for those
in the active treatment group who met the depression treatment success criteria.
In the intervention arm, participants chose PST, medication, both, or neither. PST is an
easily disseminated, manualized, problem-focused form of cognitive behavior therapy that
teaches patients how to systematically solve self-identified psychosocial problems that can
trigger and perpetuate depression.22 Initially, PST was administered over the Internet via
interactive video calls between the recruiting site and the coordinating center, with
subsequent sessions provided by video calls or telephone, either at the clinic or at the home,
depending on patient preference.23
Participants who chose pharmacotherapy were interviewed by the local study physician or
nurse practitioner, and the participant and local provider agreed on the appropriate
medication (sertraline, citalopram, or bupropion) and dosage based on the participant’s prior
medication history and current symptoms. Medication dosing followed standard clinical
practice.19 Participants were initially seen in person by the study physician or nurse at 1- to
2-week intervals for dose titration and every 3 to 5 weeks thereafter as needed. For
participants who chose pharmacotherapy but who had already been prescribed a nonstudy
antidepressant, subsequent treatment was coordinated with their initial prescribing
practitioner.
In the Usual care condition, the participant’s primary care physician and/or cardiologist was
informed by letter about the patient’s participation in the trial and his/her depressive
symptom level. The participant was free to obtain any depression care from that physician or
another provider.
OUTCOMES
The primary outcomes were change in BDI scores over 6 months and health care costs. To
estimate costs, we searched the National Death Index, actively surveyed hospital records for
ACS events, and proactively queried participants about all hospitalizations, all ambulatory
care visits, cardiac procedures, and total number of hospitalization days. Participants also
completed the Medical Outcomes Study 12-Item Short Form Health Survey (SF-12) and the
National Institutes of Health Patient Reported Outcomes Measurement Information System
(PROMIS) anxiety short form at baseline and 6 months.24,25
Statistical Analysis
The trial was powered to detect a between-group difference in the 6-month change in
depression symptoms. Assuming a 5% attrition rate, we estimated that a sample of 150
patients would be needed to have 80% power to detect a clinically meaningful differential
change in depression scores between groups of 0.46 SD.20
Baseline differences between the active treatment and usual care groups were evaluated
using the t test for continuous variables and the χ2 test for categorical variables. Latent
growth curve modeling procedures were used to generate full-information maximum-
likelihood estimates of treatment effects for the entire cohort of trial participants and by
subgroups. Primary analyses were conducted according to the intent-to-treat principle. Wald
χ2 statistics were used to test the significance of the differential change in depressive
symptoms between groups (group × time interaction).1
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Logistic regression was used to determine whether exposure to active treatment was
associated with increased risk of (1) depression remission (defined in the trial as a BDI score
<10 at 6 months), (2) improvement in depressive symptoms (defined here as ≥0.5-SD
decrease on the BDI), (3) 30 or more total depression-free days during the 6-month
intervention, (4) improvement in anxiety symptoms (≥0.5 SD on the PROMIS anxiety
scale), and (5) improvements in mental and physical functional status (≥0.5 SD on the SF-12
mental and physical health scales). We calculated the number needed to treat (NNT) as the
inverse of the absolute risk reduction associated with active treatment vs usual care for each
outcome, and for depressive symptoms we calculated a Hedges’ G effect size2.
Ambulatory care costs were based on Current Procedural Terminology codes and
Medicare’s Physician Fee Schedule for non–facility-based care, mental health costs on
appointment duration, hospitalization costs on Medicare diagnosis-related-group hospital
payments with an adjustment for physicians’ professional fees based on length of stay,26 and
antidepressant and anxiolytic medication costs on the 2010 Red Book midrange average
wholesale price for generic medications.27 All costs are presented in 2011 US dollars and
adjusted to the US Consumer Price Index. To determine whether group assignment predicted
cost outcomes, we conducted linear regression models, adjusted for age, sex, ethnicity, race,
marital status, education, baseline BDI score, type of ACS, and left ventricular ejection
fraction (see Ladapo et al28 for details).3
RESULTS
STUDY PARTICIPANTS
Potential participants with ACS (n = 724) were asked to participate in an eligibility
interview; 177 patients (24.4%) were found eligible and 150 were enrolled and randomly
allocated (Figure 1): 73 to active treatment and 77 to usual care. Two participants in each
group were lost to follow-up at 6 months, and 4 from each group (5.3% total) had missing 6-
month depression data. Table 1 provides baseline demographic and clinical characteristics
by group.
STUDY TREATMENT
Of the 73 active treatment patients, 41 (56.2%) initially chose PST, 9 (12.3%) chose
antidepressant medication, 17 (23.3%) chose both, and 6 (8.2%) chose neither. The mean
number of PST sessions for those who initially chose PST was 7.7 (range, 1–25). Of the 77
patients randomized to usual care, 9 (11.7%) received psychotherapy, and another 9 (11.7%)
received antidepressants new to their treatment regimen.
ANTIDEPRESSANT AND PSYCHOTHERAPY USE BEFORE AND AFTER THE TRIAL
Of the 150 trial participants, 25 of the active treatment and 26 of the usual care participants
reported that they were already receiving antidepressants at randomization; at the end of the
trial, 37 of the 73 active treatment participants (50.7%) and 28 of the 77 usual care
participants (36.4%) were still using antidepressants(χ2 (1) = XX, p< XX). Before
randomization, 6 (8.2%) and 9 (11.7%) patients in the active treatment and usual care
groups, respectively, were participating in psychotherapy; at the end of the trial, these
numbers had increased to 48 (65.8%) and 14 (18.2%), respectively (χ2 (1) = XX, p< XX).
1Because the distribution of BDI scores was positively skewed, all analyses were conducted using square-root transformed BDI
scores, which were then back-transformed for ease of interpretation.
2The effect size allows comparisons of the effect of an intervention across trials when different depression measures are used.
3Cost data were positively skewed but we analyzed them with parametric models without a log transformation to facilitate a more
natural interpretation, and because our inferences did not significantly change when a log-linear multivariate regression model was
used.
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The active treatment group experienced a greater reduction in BDI scores (−10.1; 95% CI,
−12.0 to −8.1) than the usual care group (−6.6; 95% CI, −8.5 to −4.8), resulting in a
significant differential change between groups of −3.5 BDI points (95% CI, −6.1 to −0.7; P
= .01; Hedges’ G = 0.59) (Figure 3). Remission of depression (BDI score <10 at 6 months)
occurred in 24 active treatment participants (47.1%) and 16 usual care participants (27.6%)
(P = .04; number needed to treat = 5). No significant differences were found between groups
in the proportion of participants who achieved a 0.5-SD reduction of depressive symptoms)
or 30 or more depression-free days (Table 2).
Exploratory post hoc subgroup analyses revealed a significant sex × group × time interaction
(P = .03); women’s depressive symptom scores decreased more (−6.4; 95% CI, −10.1 to
−2.6) than men’s (−1.6; 95% CI, −6.7 to 3.6) in active treatment group (Supplemental Table
1). There was also a significant diabetic status × group × time interaction (P = .0499); the
depressive symptom scores of patients with diabetes decreased more (−6.2; 95% CI, −10.0
to −2.3) than did those of patients without diabetes in the active treatment group (−0.9; 95%
CI, −4.6 to 2.7). No other subgroup differences were found, including the comparison of
those with probable mild (BDI 10–15) vs major (BDI ≥16) depression.
HEALTH CARE COSTS
Mental health costs were significantly higher for the active treatment group than for the
usual care group (adjusted change, +$687; 95% CI, $466 to $909; P<.001), while average
hospital costs were lower in the intervention group (adjusted change, −$1,010; 95% CI, −
$3,294 to $1,274; P=0.39). As a result of this offset, total health care costs in the study
intervention group were not higher than in the comparison group (adjusted change, −$325;
95% CI, −$2639 to $1989; P=.78; Figure 2, Supplemental Table 2).
DISCUSSION
The CODIACS Vanguard provides a basis for future studies to determine whether treating
depression reduces mortality and cardiac event recurrence in post-ACS patients. It
demonstrates that this approach yields a substantial reduction in depressive symptoms,
replicating our earlier trial finding. 14 The size of the study intervention’s effect on
depressive symptoms (Hedges’ G = 0.59) compares favorably with the results of
interventions tested in other trials. Figure 3 compares these findings with those of a prior
trial that tested a patient preference–based intervention,14 other recent depression trials in
ACS patients,29–33 and meta-analyses of both psychotherapy22 and antidepressant
medication trials.34
Post hoc testing of 10 subgroup differences identified two apparent subgroup effects: the
study intervention had stronger effects on depression reduction in women than in men, and
in patients with diabetes than in patients without diabetes. Some previous depression trials in
cardiac populations found weaker treatment effects for women than for men.33,35 Additional
studies would be required to confirm whether the study intervention employed here has
gender-specific benefits or specific benefit for depressed post-ACS patients with comorbid
diabetes.
This trial has several limitations. It enrolled patients with elevated depressive symptoms
who did not necessarily meet criteria for a major depressive disorder. Some institutional
review board committees consider any delay in treating diagnosed depression as unethical,
and the gold standard for diagnosis of major depressive disorder requires a lengthy
psychiatric interview conducted by a trained expert. Both these considerations impede the
conduct of a pragmatic RCT for post-ACS depression. In addition, even patients with
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subsyndromal depressive symptoms are at elevated risk for adverse medical outcomes and
experience impaired quality of life, suggesting that such patients may benefit from
treatment. The usual care condition did not control for the amount of clinical attention
participants received. Evidence about the usefulness of any management approach is
cumulative; other control conditions should be considered for future trials. Our estimate of
costs must be viewed as very preliminary; although our point estimate indicated a possible
cost saving associated with the study intervention, the effect was not significant and the
confidence interval was quite wide. In addition, we likely underestimated intervention costs
because we did not account for some aspects of care coordination. Finally, central
coordination of phone and internet interventions may be the treatment of the future, but may
be difficult to implement currently, given the structure of health care treatment of patients
with ACS.
The intriguing hypothesis that depression is causally implicated in ACS recurrence and
death36 has never been adequately tested despite decades of observational prospective
research reporting that elevated depressive symptoms are strongly associated with these
outcomes. Skepticism concerning this causal hypothesis12 has persisted and contributes to
uncertainty among clinicians about whether to treat post-ACS depression. To our
knowledge, no RCTs of depression treatment have definitively demonstrated a reduction in
cardiovascular disease recurrence or death. Most widely used treatments have limited
efficacy for depression reduction in post-ACS patients, impeding a proper test of the causal
hypothesis. Depressive symptoms remain on par with other established coronary heart
disease risk factors for strength of association with ACS recurrence and mortality risk.37
Cardiologists, primary care physicians, and family physicians are being urged to screen for
depression, without sufficient trial data to guide subsequent treatment. Advisories and
guidelines from the American Heart Association,38,39 American Academy of Family
Practitioners,40 European professional cardiology societies,41 and the British health care
system42 recommend depression screening in post-ACS patients and referral for treatment if
depression is found. However, no cost-effectiveness RCT data are available to inform this
large, potentially expensive guideline recommendation. There has been only one sufficiently
powered RCT on which to base treatment decisions,33 which is clearly an inadequate basis
for empirically supported practice.
We now have new signals of a substantial and possibly cost-neutral depression treatment
benefit from this and other RCTs20,43–46 on which to base a definitive ACS depression trial.
A large phase 3 trial would inform evidence-based depression treatment guidelines for
patients with an ACS, and even has the tantalizing possibility of answering the important
question of whether treating depression in ACS patients lowers mortality and recurrence
rates.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CONSORT diagram of the CODIACS Vanguard trial.
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Comparison of health care use costs during the 6 months between treatment groups.
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Comparison of the CODIACS Vanguard trial with other trials of depression treatments in
coronary heart disease and primary care patients. *This trial included participants with
elevated depressive symptoms; other trials included only patients with major depressive
disorder. It is also important to note that some of these trials had more active control
conditions, leading possibly to smaller depression differences between groups. Full-
information maximum-likelihood estimates were used to determine intent-to-treat treatment
effects; other trials may have used other estimating methods. IPT indicates interpersonal
psychotherapy.
Note: a larger Hedges’ G indicates a stronger positive effect of the tested intervention.
Note: Vertical dashed lines indicate the 95% confidence intervals for the Hedges’ G
estimates from the three meta-analyses.
Note: Horizontal solid line indicates the 95% confidence interval for each individual study
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